Carolyn C. Jackson

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.7K citations

Medicine, Hematology, Oncology +17

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong et al. · New England Journal of Medicine · 2023 · 733 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja et al. · Journal of Clinical Oncology · 2022 · 633 citations · Full text

Medicine, Hematology, Immunology +17

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Adam D. Cohen, Samir Parekh, Bianca Santomasso et al. · Blood Cancer Journal · 2022 · 270 citations · Full text

Medicine, Hematology, Oncology +17

Tuberculosis and impaired IL-23–dependent IFN-γ immunity in humans homozygous for a common <i>TYK2</i> missense variant

Stéphanie Boisson‐Dupuis, Noé Ramirez‐Alejo, Zhi Li et al. · Science Immunology · 2018 · 209 citations · Full text

Life Sciences, Genetics, Immunology +13